Dexamethasone therapy in COVID‐19 patients: implications and guidance for the management of blood glucose in people with and without diabetes.

Autor:	Rayman, G., Lumb, A. N., Kennon, B., Cottrell, C., Nagi, D., Page, E., Voigt, D., Courtney, H. C., Atkins, H., Higgins, K., Platts, J., Dhatariya, K., Patel, M., Newland‐Jones, P., Narendran, P., Kar, P., Burr, O., Thomas, S., Stewart, R.
Předmět:	BLOOD sugar BLOOD sugar monitoring DIABETES PATIENT aftercare INSULIN DEXAMETHASONE GLYCEMIC control COVID-19
Zdroj:	Diabetic Medicine; Jan2021, Vol. 38 Issue 1, p1-5, 5p
Abstrakt:	The article discusses that high doses of glucocorticoids exacerbate hyperglycaemia in people with diabetes. It mentions that glucocorticoids are the commonest cause of people with diabetes developing potentially life-threating hyperglycaemic hyperosmolar state (HHS) in hospital. It also mentions that COVID-19 infection is associated with significant insulin resistance.
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text